As specialty pharmaceutical spending continues to climb, healthcare plan sponsors face a critical decision: how to balance patient access with long-term financial viability. With U.S. prescription drug spending reaching approximately $467 billion in 2024 and projections indicating costs could exceed $556 billion by the end of 2026, the pressure to implement a sustainable specialty drug strategy has never been greater. For employers and pharmacy benefit managers (PBMs), the path forward involves choosing between alternative funding programs and more integrated in-benefit optimization strategies.
The core of this challenge lies in managing high-cost therapies that are clinically necessary but place immense strain on health plan budgets. To address this, organizations are increasingly evaluating two primary models: Alternative Funding Programs (AFPs) and in-benefit optimization. While both aim to curb rising expenditures, they operate through fundamentally different operational pathways and require distinct management guardrails to ensure they remain compliant and effective.
Understanding Alternative Funding Programs
Alternative funding programs (AFPs) are designed to manage high-cost specialty drug spend by utilizing alternative sourcing pathways. These programs often coordinate access through manufacturer patient assistance programs (PAPs) or other external mechanisms to improve affordability for members. By shifting the sourcing of specific high-cost medications outside of the traditional pharmacy benefit, plan sponsors can achieve significant savings in concentrated areas of spend.
However, implementing an AFP is not a simple “plug-and-play” solution. It requires robust coordination across various stakeholders, including pharmacies, drug manufacturers, and specialized support programs. Because these models often introduce additional layers of documentation and communication, plan sponsors must carefully evaluate the operational burden alongside the potential financial return. For an AFP to be a viable component of a broader cost-management strategy, it must be applied with clear, defensible guardrails that do not compromise the patient’s access to life-saving or chronic condition therapies.
The Mechanics of In-Benefit Optimization
In-benefit optimization takes a different approach by focusing on waste reduction within existing pharmacy benefit structures. Rather than sourcing drugs through external pathways, this model leverages unified platforms to identify and eliminate inefficiencies directly within the current workflow. This is particularly effective for addressing common sources of excess spend, such as duplicative or overlapping therapies, oversupply issues, and the occurrence of early refills.
By integrating data-driven, algorithm-guided recommendations into the prescriber’s workflow, PBMs can reduce unnecessary therapy usage without disrupting the patient’s continuity of care. This approach also helps address the issue of regimen complexity; when a treatment plan is too difficult to follow, patient adherence drops, which negatively impacts both health outcomes and employer margins. Automated drug-spend intelligence platforms can streamline these processes, allowing plan sponsors to optimize pricing in real-time based on drug availability, policy changes, and fluctuating costs.
Establishing Sustainable Guardrails
Whether a plan sponsor chooses to implement an AFP, an in-benefit optimization platform, or a hybrid model, the strategy must be built upon non-negotiable requirements to ensure defensibility and long-term success. These guardrails serve as the foundation for a sustainable drug-spend strategy:
- Continuity of Care: The strategy must preserve the patient’s existing therapy and regimen without interruption.
- Administrative Efficiency: The process should ease, rather than exacerbate, the administrative workload for prescribers.
- Regulatory Compliance: All financial pathways must be transparent, defensible to auditors, and strictly within established compliance boundaries.
- Documented Savings: The program must produce clear, measurable data to validate the effectiveness of the cost-reduction efforts.
By leveraging technology to operationalize these steps, plan sponsors can move beyond reactive spending cuts and toward proactive, sustainable margin protection. The goal is to create a system that is not only financially sound but also supports the well-being of the member by tracking adherence and minimizing potential escalations or complaints.
Designing a Future-Proof Strategy
The affordability crisis in specialty pharmaceuticals is not a temporary trend, but a structural reality that requires a sophisticated response. PBMs and plan sponsors that successfully navigate this environment are those that treat data-driven optimization as a core operational competency. By layering analytics-powered systems with clear guardrails, organizations can achieve a more stable benefit design that remains resilient against rising pharmaceutical costs.
As the industry moves toward 2026, the focus will likely shift further toward refining these digital tools to ensure that specialty drug benefits remain both clinically appropriate and financially sustainable. For stakeholders, the next step involves a thorough audit of current pharmacy workflows to identify where waste exists and where targeted, technology-enabled interventions can yield the most significant, defensible savings.
We welcome your insights on how your organization is managing specialty drug costs. Please share your experiences or questions in the comments section below as we continue to track developments in pharmaceutical benefit strategy and healthcare policy.